Data / Drug companies / Elysium Pharmaceuticals Ltd.
Elysium Pharmaceuticals Ltd.: 28 products in the FDA NDC directory, labeler code 14803
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Elysium Pharmaceuticals Ltd. (labeler code 14803) lists 28 products in the FDA National Drug Code Directory. By type: 23 over the counter drugs, 4 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on January 1, 2026.
The request: Watch Elysium Pharmaceuticals Ltd. (FDA labeler code 14803): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 14803
- Products in commercial distribution
- 28
- Packages
- 29
- Finished drugs by generic name
- 0
- Prescription products
- 1
- Over the counter products
- 23
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- November 19, 2020
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 28 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 23 | 82.1% |
| Drugs for further processing | 4 | 14.3% |
| Prescription drugs | 1 | 3.6% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 14 | 50% |
| Capsule, liquid filled | 8 | 28.6% |
| Capsule | 3 | 10.7% |
| Tablet, film coated | 1 | 3.6% |
| Tablet, for solution | 1 | 3.6% |
| Tablet, delayed release | 1 | 3.6% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Acetaminophen diphenhydramine and phenylephrine hydrochloride | 14803-303 | Tablet | Drugs for further processing | January 1, 2026 |
| Diphenhydramine hydrochloride 25 | 14803-912 | Capsule | Drugs for further processing | September 1, 2025 |
| Phenylephrine hydrochloride | 14803-003 | Tablet | Drugs for further processing | August 1, 2025 |
| Simethicone | 14803-911 | Capsule, liquid filled | Drugs for further processing | June 24, 2025 |
| Simethicone 180 | 14803-910 | Capsule, liquid filled | Drugs for further processing | March 1, 2025 |
| Acetaminophen, dextromethorphan hydrobromide, doxylamine succinate | 14803-047 | Capsule, liquid filled | Drugs for further processing | January 23, 2025 |
| Acetaminophen, dextromethorphan hydrobromide, phenylephrine hydrochloride | 14803-046 | Capsule, liquid filled | Drugs for further processing | January 23, 2025 |
| Sennosides tablets 8.6 | 14803-305 | Tablet | Drugs for further processing | January 1, 2025 |
| Acetaminophen, diphenhydramine hydrochloride | 14803-174 | Tablet | Drugs for further processing | December 11, 2024 |
| Acetaminophen ,dextromethorphan hydrobromide, doxylamine succinate | 14803-902 | Capsule | Drugs for further processing | November 28, 2024 |
| Sodium chloride | 14803-304 | Tablet, for solution | Drugs for further processing | March 7, 2024 |
| Diphenhydramine hydrochloride (blue) | 14803-302 | Tablet, film coated | Drugs for further processing | March 7, 2024 |
| Acetaminophen | 14803-281 | Tablet | Drugs for further processing | March 7, 2024 |
| Acetaminophen | 14803-281 | Tablet | Drugs for further processing | March 7, 2024 |
| Aspirin | 14803-206 | Tablet, delayed release | Drugs for further processing | March 7, 2024 |
| Acetaminophenand caffeine | 14803-151 | Tablet | Drugs for further processing | March 7, 2024 |
| Acetaminophen | 14803-013 | Tablet | Drugs for further processing | March 7, 2024 |
| Acetaminophen 325mg, guaifenesin 200mg, dextromethorphan hbr 10mg, phenylephrine hcl 5 mg | 14803-913 | Capsule, liquid filled | Drugs for further processing | March 1, 2024 |
| Acetaminophen, dextromethorphan hydrobromide and phenylephrine hydrochloride | 14803-909 | Capsule, liquid filled | Drugs for further processing | March 1, 2024 |
| Acetaminophen dextromethorphan hydrobromide doxylamine succinate and phenylephrine hydrochloride | 14803-907 | Capsule, liquid filled | Drugs for further processing | March 1, 2024 |
| Guaifenesin and dextromethorphan hbr | 14803-306 | Tablet | Drugs for further processing | February 7, 2024 |
| Guaifenesin | 14803-162 | Tablet | Drugs for further processing | February 7, 2024 |
| Acetaminophen pyrilamine maleate and caffeine | 14803-118 | Tablet | Drugs for further processing | February 7, 2024 |
| Acetaminophen aspirin and caffeine | 14803-135 | Tablet | Drugs for further processing | January 30, 2024 |
| Dextromethorphan hydrobromide capsules | 14803-904 | Capsule, liquid filled | Drugs for further processing | January 1, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.